Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 22, Issue 7, Pages 529-530Publisher
NATURE PORTFOLIO
DOI: 10.1038/d41573-023-00100-1
Keywords
-
Ask authors/readers for more resources
Shiva Malek, head of oncology at Novartis Institutes for Biomedical Research, talks about her ambitions in drug development, including drugging transcription factors, addressing drug resistance, and finding a cure for KRAS-mutant cancer.
Shiva Malek, head of oncology at Novartis Institutes for Biomedical Research, discusses her drug development ambitions - including drugging transcription factors, tackling drug resistance and curing KRAS-mutant cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
